Novartis AG (NOVN) - Stock Price & Dividends

Exchange: SIX Swiss Exchange • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0012005267

Prescription Medicines, Cardiovascular Drugs, Cancer Treatments

Novartis AG is a Swiss-based healthcare giant that pioneers in the research, development, manufacturing, and marketing of innovative healthcare products globally.

The company's primary focus is on creating prescription medicines that cater to the diverse needs of patients and physicians worldwide. Its therapeutic areas of expertise include cardiovascular diseases, renal and metabolic disorders, immunology, neuroscience, oncology, ophthalmology, and hematology.

Novartis AG has formed strategic partnerships to accelerate its mission. For instance, it has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a groundbreaking therapy designed to reduce LDL cholesterol levels. Additionally, the company has partnered with Dawn Health to develop and commercialize Ekiva, a digital solution tailored for individuals living with Paroxysmal Nocturnal Hemoglobinuria.

With a rich history dating back to 1996, Novartis AG is headquartered in Basel, Switzerland, and continues to drive innovation in the healthcare industry. For more information, visit their official website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Novartis AG (NOVN) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Novartis AG (NOVN) - Stock Price & Dividends

NOVN Stock Overview

Market Cap in USD 213,760m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception

NOVN Stock Ratings

Growth 5y 44.9
Fundamental 55.6
Dividend 6.97
Rel. Performance vs Sector -0.04
Analysts -
Fair Price Momentum 89.72 CHF
Fair Price DCF 136.32 CHF

NOVN Dividends

Yield 12m 3.51%
Yield on Cost 5y 4.73%
Dividends CAGR 5y 2.34%
Payout Consistency 100.0%

NOVN Growth Ratios

Growth 12m 13.46%
Growth Correlation 12m 58%
Growth Correlation 3m 67%
CAGR 5y 6.10%
CAGR/Mean DD 5y 0.84
Sharpe Ratio 12m 0.51
Alpha vs SP500 12m -0.70
Beta vs SP500 5y weekly 0.40
ValueRay RSI 59.00
Volatility GJR Garch 1y 16.95%
Price / SMA 50 3.25%
Price / SMA 200 8.95%
Current Volume 11200.9k
Average Volume 20d 3513k

External Links for NOVN Stock

Fund Manager Positions
What is the price of NOVN stocks?
As of June 22, 2024, the stock is trading at CHF 93.99 with a total of 11,200,938 shares traded.
Over the past week, the price has changed by -1.07%, over one month by +0.11%, over three months by +8.38% and over the past year by +13.67%.
What are the forecast for NOVN stock price target?
According to ValueRays Forecast Model, NOVN Novartis AG will be worth about 98 in June 2025. The stock is currently trading at 93.99. This means that the stock has a potential upside of +4.21%.
Issuer Forecast Upside
Wallstreet Target Price 86.9 -7.52
Analysts Target Price - -
ValueRay Target Price 98 4.21

Novartis AG: A Comprehensive Overview

Novartis AG, a leading global healthcare company based in Switzerland, has a rich history and a significant presence in the pharmaceutical industry. Established from the merger of Ciba-Geigy and Sandoz in 1996, Novartis has consistently been at the forefront of research and development, bringing innovative healthcare solutions to the market.

The Core of Novartis

At its core, Novartis focuses on three main business areas: Pharmaceuticals, which develop and market innovative patented medicines; Alcon, specializing in eye care products and procedures; and Sandoz, a leader in generic pharmaceuticals and biosimilars. This diversified portfolio allows Novartis to make substantial contributions across a broad spectrum of healthcare needs.

Side Businesses and Ventures

Beyond its primary segments, Novartis also invests in healthcare research and technologies. The company has demonstrated a commitment to cutting-edge biotechnology and digital health solutions. Through collaborations and investments, Novartis seeks to foster innovation that can enhance patient care and streamline healthcare services.

Current Market Status

As of the current market environment, Novartis AG remains a strong player in the pharmaceutical industry. Its consistent investment in R&D and strategic acquisitions have bolstered its market position. Despite the competitive and regulatory challenges, the company's focus on high-growth areas, such as gene therapy and digital health solutions, positions it well for future growth.

Note: The healthcare landscape is highly dynamic, with scientific advancements and regulatory shifts continually shaping the market. Novartis's agility in responding to these changes has been crucial to its sustained success.

Overall, Novartis AG stands as a testament to the enduring importance of innovation, strategic diversification, and a steadfast commitment to enhancing health outcomes worldwide.